On the other hand, expression of some APOE variants, like APOE4, is associated with an improved responsiveness of melanoma patients to anti-PD1 ICT, suggesting that both APOE and TREM-2 expressions on myeloid cells can be used to stratify patients who might benefit from this therapeutic strategy. This evidence concerns the gene APOE and melanoma.